Abstract. The contactin 1 (CNTN1) gene exerts oncogene-like activities and its expression has been linked to several human malignancies. In this study, a possible association between CNTN1 expression and clinicopathological parameters and clinical outcomes in patients with oral squamous cell carcinoma (OSCC) was examined. CNTN1 protein expression was evaluated by immunohistochemistry in OSCC tissues of 45 patients. For the immunohistochemical assessment of CNTN1 expression, the cytoplasmic staining labeling index was analyzed using a semiquantitative score. The association between CNTN1 protein levels and clinicopathological factors was analyzed using the Mann-Whitney U test for categorical variables and the Kruskal-Wallis test for continuous variables. The effects of CNTN1 expression on overall and disease-free survival were assessed by using univariate survival analysis. The transcript levels of CNTN1 were detected in OSCC cell lines. In addition, specific siRNA against CNTN1 was applied to investigate the effect exerted by CNTN1 ablation on OSCC cell lines by proliferation and invasion assays in vitro. During follow-up, 16 patients (35.56%) had succumbed to OSCC; the median follow-up of patients was 5.0 years (range, 0.2-8.3). A high expression of CNTN1 was markedly associated with the regional lymph node metastasis of patients with OSCC (P= 0.006). CNTN1 expression was significantly associated with overall survival of patients with OSCC (P=0.032; logrank test) and disease-free survival of patients with OSCC (P=0.038; log-rank test). In addition, CNTN1 ablation notably suppressed the invasion potential of OSCC cell lines, but there was no significant change in the proliferation of OSCC cell lines by CNTN1 knockdown in vitro. The study supports CNTN1 as a novel predictor of regional lymph node metastasis in patients with OSCC and a prognostic marker for OSCC in patients.
Introduction
Oral squamous cell carcinoma (OSCC) accounts for more than 90% of oral cavity tumors. With approximately 8000 mortalities per year nationally, it constitutes approximately 3% of all cancer cases in the United States and is one of the six most frequent types of cancer worldwide (1) . Although tobacco and alcohol are regarded as primary risk factors, it is clear that genetic and epigenetic factors contribute to this cancer (2) . On this basis, novel molecular markers involved in OSCC development and progress should be investigated.
The protein encoded by the CNTN1 gene is a member of the immunoglobulin superfamily, which includes N-CAM, L1 and Nr-CAM. CNTN1 is a glycosylphosphatidylinositol (GPI)-anchored neuronal membrane protein that functions as a cell adhesion molecule (3) . It mediates cell surface interactions during nervous system development, involving the formation of paranodal axo-glial junctions in myelinated peripheral nerves and signaling between axons and myelinating glial cells via its association with CNTNAP1. In addition, as a ligand of Notch1, CNTN1 promotes Notch1 activation which is involved in oligodendrocyte generation through the released notch intracellular domain (NICD) and subsequent translocation to the nucleus (4) . However, it is becoming increasingly evident that certain members of this immunoglobulin superfamily facilitate the motility, invasion and metastasis of cancer (5, 6) . Additionally, the location of CNTN1 in the 12q11-q12 chromosomal region, which is a breakpoint region in several types of cancer, suggests that CNCT1 is involved in tumor formation or progression.
Notably, in vitro silencing of CNTN1 expression may inhibit the invasive and metastatic ability of lung adenocarcinoma (7) . Furthermore, VEGF-C/Flt-4-mediated invasion and metastasis of cancer cells were found to be through the upregulation of the neural cell adhesion molecule CNTN1 which activated the Src-p38 MAPK-C/EBP-dependent pathway (8) . In view of its malignant phenotype-promoting activities in cancer cells and its growth-promoting abilities in neural cells, this study investigated the possibility of CNTN1 as a prognostic marker for patients with OSCC and the association between CNTN1 expression and metastasis of OSCC in vivo. CNTN1 protein levels were evaluated in 45 primary OSCC specimens by immunohistochemistry. Our study demonstrates that CNTN1 protein level was markedly associated with lymph node metastasis of patients with OSCC (P=0.006). CNTN1 expression was significantly associated with overall survival of patients with OSCC (P=0.032; log-rank) and disease-free survival of patients with OSCC (P=0.038; log-rank). In vitro results revealed that CNTN1 ablation was able to inhibit the invasion potential of OSCC cells, but not proliferation of OSCC cells. We conclude that CNTN1 is a novel and powerful factor for the metastasis and prognosis of OSCC patients. were cultured in RPMI-1640 medium (Gibco-BRL, Carlsbad, CA, USA) supplemented with 10% heat-inactivated fetal bovine serum (FBS; Gibco-BRL), penicillin (100 U/ml) and streptomycin (100 µg/ml) at 37̊C in a humidified 5% CO 2 atmosphere. CAL27 (American Type Culture Collection, Manassas, VA, USA) was cultured in Dulbecco's modified Eagle is medium (DMEM; Gibco BRL) supplemented with 10% heat-inactivated FBS (Gibco BRL), penicillin (100 U/ml) and streptomycin (100 µg/ml) at 37˚C in a humidified 5% CO 2 atmosphere.
Patients and methods

Patients
Immunohistochemistry. The avidin-biotin complex (ABC) technique was performed using a Vectastain Elite ABC kit (Vector Laboratories, Inc., Burlingame, CA, USA). Briefly, paraffin-embedded tissue sections were dewaxed and rehydrated using xylene and a series of graded alcohols. To determine antigenicity, slides were steamed with 10 mmol/l citrate buffer (pH 6.0; DAKO/Cytomation, Glostrup, Denmark) for 20 min. Endogenous peroxidase activity was quenched by immersing the slides in 3% hydrogen peroxide in double-distilled water for 20 min. Tissue sections were blocked with 10% normal horse serum for 30 min at room temperature. The slides were then incubated with monoclonal anti-CNTN1 antibody at 1:100 dilution (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) at 4˚C overnight. Each section was treated with biotinylated-secondary antibody for 30 min at room temperature. Diaminobenzidine was used as the chromogen for the immunoperoxidase reaction and the slides were counterstained with Mayer's hematoxylin (DAKO/Cytomation). Sections were thoroughly washed, glass covered and analysed by light microscopy, using a magnification of up to x400. For the immunohistochemical assessment of CNTN1 expression, the frequency of cytoplasmic staining was evaluated using a semiquantitative score: 0-1, from negativity to positivity in <50% (low expression); 2, positivity in >50% (high expression). The score of each lesion was the average of the indices generated by two observers (W.C. and H.M.W.) blinded to the clinical information. The differences between the two observers were <10% in almost all cases.
Reverse transcription-polymerase chain reaction (RT-PCR)
analysis. High quality total RNA (2 µg) was directly processed to cDNA using the reverse transcription kit (Promega, Madison, WI, USA), following the manufacturer's instructions, in a total volume of 25 µl. The primer sequences used were: CNTN1, forward: 5'-CAACAAAACCATATCCTGCTGA-3'; reverse: 5'-AGATCACTGCCTATGTCCACCT-3'; β-actin, forward: 5'-TCACCCACACTGTGCCCATCTACGA-3'; reverse: 5'-CAGCGGAACCGCTCATTGCCAATGG-3'; Each primer was added at a final concentration of 0.5 µM to a 15 µl reaction mixture in PCR buffer, containing 1 µl cDNA, 0.25 mM of each dNTPs, 1.5 mM MgCl 2 and 2.5 units Taq DNA polymerase. An initial denaturation was conducted for 5 min at 94˚C and 35 cycles were performed with the following PCR program: denaturation at 94˚C for 30 sec, annealing at 45 for 60˚C for CNTN1 for 30 sec and 55˚C for β-actin for 30 sec, elongation at 72˚C for 30 sec, followed by a final extension of 5 min at 72˚C. Ethidium bromidestained bands were visualized by UV transillumination and the fluorescence intensity was quantified using the FR-200 system (Shanghai FURI Science and Technology Co., Ltd., Shanghai, China). RT-PCR data were from at least three independent experiments.
Small interfering RNA (siRNA) knockdown. Two siRNAs against CNTN1 were designed and chemically synthesized (Shanghai GenePharma Co., Ltd., Shanghai, China). The siRNA which had a greater silencing effect was selected for further study, with the following sequence: CNTN1-siRNA_1697: Invasion assays. A total of 1x10 5 various cells in 750 µl serum-free RPMI-1640 medium were plated onto a BD BioCoat TM Matrigel TM Invasion Chamber (8 µm pore size; BD Biosciences, Franklin Lakes, NJ, USA) and the lower chamber was immediately filled with 750 µl of RPMI-1640 medium with 10% FBS as a chemoattractant. After 48 h of incubation in a humidified atmosphere containing 5% CO 2 at 37˚C, the non-invading cells were removed from the upper surface of the membrane by a cotton swab and the membranes were then fixed with methanol and stained with 0.5% crystal violet. Invading cells were captured and counted in five random non-overlapping fields under a light microscope (magnification, x100).
Statistical analysis.
The associations between CNTN1 expression status and clinicopathological parameters were analyzed using the Mann-Whitney U test and the Kruskal-Wallis test for categorical variables. The probability of overall survival and disease-free survival by CNTN1 protein expression was determined using the Kaplan-Meier method. Paired t-test was used for analysis of the in vitro studies. Analyses were conducted using SAS 9.1.3 software. The tests were two-sided, and P<0.05 was considered to indicate a statistically significant difference. Table I . Correlation between CNTN1 expression and patient characteristics. 
CNTN1 expression (No. of cases) --------------------------------------
Results
Correlation between CNTN1 expression and patient characteristics.
To identify the association between CNTN1 expression and clinicopathological factors, the expression of CNTN1 was analyzed in 45 primary OSCCs by immunohistoprimary OSCCs by immunohistoprimary OSCCs by immunohistochemistry. Positive lesions demonstrated clearly membrane or cytoplasmic localization of the CNTN1 protein (Fig. 1) , which is consistent with its function in cells. Distribution of the CNTN1 expression status and associations with general clinicopathological parameters are shown in Table I . Of 45 patients enrolled in this study, 12 (26.7%) patients had regional lymph node metastasis to a certain extent. Furthermore, 9 (75%) of 12 (26.7%) patients with regional lymph node metastasis revealed a high expression level of CNTN1, whereas 22 (66.7%) of 33 (73.33%) patients without regional lymph node metastasis revealed a low expression level of CNTN1. A significantly high expression level of CNTN1 was found to be markedly association with patients who had regional lymph node metastasis. Additionally, no statistically significant correlation was found between CNTN1 protein level and other clinicopathological factors, including age (P=0.063), gender (P=0.064), clinical TNM classification (P= 0.069), pathological grade (P= 0.527) and tumor recurrence (P=0.640).
CNTN1 expression and patient survival.
To determine whether CNTN1 protein expression is a prognostic marker for patients with OSCC, the overall and the disease-free survival of OSCC were calculated using the log-rank test and curves were constructed using the Kaplan-Meier method (Fig. 2) . The median follow-up of patients was 5.0 years (range, 0.2-8.3). During the follow-up of 45 patients, 16 patients (35.56%) succumbed to OSCC. Of these 16 patients, 6 patients (37.5%) demonstrated a low protein level of CNTN1, while 10 patients (62.5%) demonstrated a high protein level of CNTN1. The survival of patients with OSCC was calculated from the time of radical surgery until the end of the follow-up. The diseasefree survival rate at 3 and 5 years after radical surgery for the whole cohort of patients was 71.11 and 64.44%, respectively. Survival analysis revealed that CNTN1 expression was significantly associated with overall survival of patients with OSCC (P=0.032; log-rank) and disease-free survival of patients with OSCC (P=0.038; log-rank).
Effect of CNTN1 ablation on cell proliferation of OSCC cell lines.
To evaluate whether CNTN1 promotes malignant phenotypes of OSCC cells, we firstly assessed the effect of CNTN1 ablation on cell proliferation of OSCC cell lines. Based on the CNTN1 expression pattern in OSCC-derived (Fig. 3A) , we transiently transfected target CNTN1 siRNA, negative control siRNA_NC and Lipofectamine 2000-only to OSC-4 and Cal-27 cells, all of which have endogenous CNTN1 mRNA expression (Fig. 3B) . However, our results demonstrated that silencing CNTN1 did not remarkably inhibit the proliferation of OSCC cells compared to cells transfected with siRNA_NC control (Fig. 4A) . Furthermore, in vitro invasion assays were performed to determine the effect of CNTN1 on cell invasion using a BD BioCoat Matrigel Invasion Chamber. The Matrigel matrix served as a reconstituted basement membrane in vitro. Moreover, the number of cells invading through the transwell membrane in OSC-4 transfected with siRNA_1697 and Cal-27 transfected with siRNA_1697 was significantly lower than those transfected with siRNA_NC, respectively (P<0.01) (Fig. 4B) .
Discussion
As one of the most common types of epithelial cancer, the incidence of oral squamous cell carcinoma (OSCC) is the sixth highest worldwide (11) . Traditional treatments, including radical surgery, radiotherapy and chemotherapy, have not sufficiently improved the five-year survival rate of patients with this disease in more than two decades. Moreover, the development of OSCC is evolutionary and characterized by multistep carcinogenic processes, in which the activation of oncogenes and inactivation of tumor suppressor genes are key features leading to OSCC progression. Considering these factors, the identification of useful predictors or targets of OSCC for diagnosis, therapy and prognosis is promising. Although numerous studies have been conducted, few useful molecular predictors or targets for OSCC have been identified. CNTN1 is a novel member of the contactin subgroup of the immunoglobulin superfamily which also includes contactin-2, 5 and 6. The well-known role of these proteins and ligands is the repulsive guidance of nerve axons, regulating neurite extension in a mouse neuroblastoma cell line and primary hippocampal neurons (12) (13) (14) . In addition, mutations in the CNTN1 gene causing a familial type of lethal congenital myopathy have been reported (15) . In addition to A B its regulatory role in the nervous system, CNTN1 functions as a glycosylphosphatidylinositol anchor neural cell adhesion molecule (NCAM), which is involved in tumor cell adhesion, invasion and metastasis (16) (17) (18) . CNTN1 was first described as a metastasis-promoting oncogenic protein by Su et al (7, 8) . Suppression of CNTN1 expression abolished the ability of lung cancer cells to invade and metastasize by activating RhoA, but not Cdc42 or Rac1, suggesting that CNTN1 is a key regulator of invasion and metastasis in lung adenocarcinoma (7) . Considering the particularity of OSCC in epidemiology, which is notably different from other cancer types, as well as the different molecule signatures in invasion and metastasis, in this study, we investigated whether CNTN1 is a major factor promoting OSCC progression and metastasis. Experimental results demonstrated that CNTN1 expression is markedly associated with regional lymph node metastasis (P=0.006) in patients with OSCC and silencing CNTN1 decreased the invasion potential of OSCC cells, confirming that CNTN1 is a powerful factor involved in invasion and metastasis in OSCC. Notably, CNTN1 ablation exerted little effect on the proliferation of OSCC cells, indicating that CNTN1 promotes malignant phenotypes of OSCC by exclusively activating the metastastic potential.
Our data demonstrated that CNTN1 expression was significantly associated with the overall survival of patients with OSCC (P=0.032; log-rank test) and disease-free survival of patients with OSCC (P=0.038; log-rank test) by univariate analysis. Thus, CNTN1 may be a novel predictor of clinical outcome for patients with OSCC.
